product1 publisher
Pediatricians are putting 8-year-olds on GLP-1s four years below the label age
Semaglutide's approval starts above age 12 and tirzepatide's obesity approval at 18, but a published study and one Dallas hospital's own count both show children under 12 already taking these drugs, mostly for obesity and type 2 diabetes.
Publishers:gizmodo.com
Reality
- Evidence48
- Adoption52
- Hype gap+15
- Incentives62
- Confidence45